Document:

<PAGE>
                                                                   EXHIBIT 10.31

                           LOAN MODIFICATION AGREEMENT

This Loan Modification Agreement is entered into as of April 29, 2002, by and
between Intrabiotics Pharmaceuticals, Inc. (the "Borrower") and Silicon Valley
Bank ("Bank").

1. DESCRIPTION OF EXISTING OBLIGATIONS: Among other Obligations which may be
owing by Borrower to Bank, Borrower is indebted to Bank pursuant to, among other
documents, an Amended and Restated Loan and Security Agreement, dated August 20,
2001, as may be amended from time to time, (the "Loan Agreement"). The Loan
Agreement provides for, among other things, a Committed Revolving Line in the
original principal amount of Two Million Five Hundred Thousand Dollars
($2,500,000) and a Term Loan in the original principal amount of Seven Million
Five Hundred Thousand Dollars ($7,500,000). Defined terms used but not otherwise
defined herein shall have the same meanings as set forth in the Loan Agreement.

Hereinafter, all indebtedness owing by Borrower to Bank shall be referred to as
the "Obligations."

2. DESCRIPTION OF COLLATERAL. Repayment of the Obligations is secured by the
Collateral as described in the Loan Agreement and in an Intellectual Property
Security Agreement.

Hereinafter, the above-described security documents and guaranties, together
with all other documents securing repayment of the Obligations shall be referred
to as the "Security Documents". Hereinafter, the Security Documents, together
with all other documents evidencing or securing the Obligations shall be
referred to as the "Existing Loan Documents".

3. DESCRIPTION OF CHANGE IN TERMS.

        A.    Modification(s) to Loan Agreement.

               1.     Notwithstanding anything to the contrary contained under
                      Section 2.1.1 entitled "Revolving Advances", upon Bank's
                      receipt of evidence of Borrower's satisfactory completion
                      of the Performance Covenant, Borrower shall have the
                      option prior to the Revolving Maturity Date to amortize
                      the outstanding Advances under the Committed Revolving
                      Line in 36 equal monthly payments of principal plus
                      interest beginning 30 days following the date of
                      amortization and continuing on the same day of each month
                      thereafter (the "Amortizing Term Loan"). The final payment
                      for the Amortizing Term Loan due on the 36th month
                      following the date of amortization, however no later than
                      August 20, 2005 (the "Amortizing Term Loan Maturity
                      Date"), shall be for all outstanding principal plus all
                      accrued unpaid interest. Amounts repaid under the
                      Amortizing Term Loan may not be reborrowed.

                      The Amortizing Term Loan accrues interest at a per annum
                      rate of 1.50 percentage points above the Prime Rate. After
                      an Event of Default, Obligations accrue interest at 5
                      percentage points above the rate immediately before the
                      Event of Default. The interest rate increases and
                      decreased when the Prime Rate changes. Interest is
                      computed on a 360 day year for the actual number of days
                      elapsed.

               2.     Sub Section (a) under Section 2.4 entitled "Interest Rate,
                      Payments" is hereby amended in part to read to provide
                      that beginning with the first day of the month following
                      Bank's receipt of satisfactory evidence of Borrower's
                      completion of the Performance Covenant, the Term Loan
                      shall accrue interest at a per annum rate of 1.50
                      percentage points above the Prime Rate then in effect.

               3.     Notwithstanding anything to the contrary contained under
                      Sections 6.2 entitled "Financial Statements, Reports,
                      Certificates" and Section 6.7 entitled "Financial
                      Covenants" Bank shall no longer require Borrower to comply
                      with the Weekly
<PAGE>

                      Reporting requirements, as provided therein. Accordingly,
                      Borrower shall comply with the Monthly Reporting, as
                      applicable.

               4.     Section 6.6 entitled "Primary Accounts" is hereby amended
                      to read as follows:

                      Borrower will maintain its primary operating accounts with
                      Bank. Additionally, Borrower will maintain the greater of
                      either (i) $20,000,000 or (ii) 33% of its total cash and
                      cash equivalents, (as shown on Borrower's financial
                      statement), in accounts with Bank or invested through
                      Bank. Additionally, in the event Borrower transfers a
                      portion of its investments and/or deposits to another
                      financial institution, Borrower shall cause an Account
                      Control Agreement to be executed between Bank and such
                      financial institution prior to such transfer.

               5.     Sub section (i) under Section 6.7 entitled "Financial
                      Covenants" is hereby amended in part to provide that
                      "Liquidity" is defined as a ratio of unrestricted cash
                      (and equivalents) divided by all Bank term debt.

               6.     Sub section (iii) under Section 6.7 entitled "Financial
                      Covenants" is hereby amended in part to provide that
                      Borrower will maintain a Remaining Months Liquidity of at
                      least 3 months. Remaining Months Liquidity is defined as
                      Liquidity minus all Bank term debt divided by the monthly
                      Net Cash Loss.

               7.     Section 6.8 entitled "Performance Covenant" is hereby
                      amended to read as follows:

                      Borrower will submit to Bank on or prior to May 10, 2002
                      evidence of its satisfactory completion from the phase III
                      clinical trial evaluating the safety and efficacy of
                      iseganan HCI oral solution in patients receiving
                      radiotherapy for cancer of the head and neck.

               8.     Section 6.9 entitled "Cash Collateral" is hereby amended
                      in part to include all Bank term debt (including the Term
                      Loan and the Amortizing Term Loan, if applicable) for
                      calculation purposes.

               9.     Notwithstanding anything to the contrary contained in
                      Section 7.1 entitled "Dispositions", Bank hereby consents
                      to the release and Borrower's sales of certain
                      Intellectual Property of Borrower pursuant to an Asset
                      Purchase Agreement between Borrower and Micrologix
                      Biotech, Inc. subject to Bank's satisfactory review and
                      acceptance of the definitive Asset Purchase Agreement.

               10.    The following defined terms under Section 13.1 entitled
                      "Definitions" are hereby amended, deleted and/or
                      incorporated to read as follows:

                      "Amortizing Term Loan" is defined under Section 2.1.1.

                      "Amortizing Term Loan Maturity Date" is defined under
                      Section 2.1.1.

                      "Monthly Reporting" applies at such times as Borrower's
                      Liquidity falls below (i) 2.50 times the outstanding
                      balance under the Term Loan and the Committed Revolving
                      Line (or the Amortizing Term Loan, if applicable) or (ii)
                      6 months Remaining Months Liquidity (as defined in Section
                      6.7).

                      "Revolving Maturity Date" is the earlier of (i) August 20,
                      2002 or (ii) Borrower's election to convert the
                      outstanding Advances into an Amortizing Term Loan,
                      (subject to the terms and conditions herein) at which time
                      the Amortizing Term Loan Maturity Date shall be effective.

<PAGE>

                      "Weekly Reporting" is hereby deleted in its entirety.

        B.    Conditional Release of Certificate of Deposit.

                      Borrower hereby reaffirms that Bank has had a perfected
                      security interest in Borrower's Certificate of Deposit
                      #8800053649 (the "CD"). Upon Borrower's election to
                      convert outstanding Advances to the Amortizing Term Loan
                      (subject to the terms and conditions herein), Bank hereby
                      agrees to release its hold placed on such CD.

4. CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever
necessary to reflect the changes described above.

5. NO DEFENSES OF BORROWER. Borrower (and each guarantor and pledgor signing
below) agrees that, as of the date hereof, it has no defenses against paying any
of the Obligations.

6. PAYMENT OF LOAN FEE. Borrower shall pay Bank a fee in the amount of Seven
Thousand Five Hundred and 00/100 Dollars ($7,500.00) ("Loan Fee") plus all
out-of-pocket expenses.

7. CONTINUING VALIDITY. Borrower (and each guarantor and pledgor signing below)
understands and agrees that in modifying the existing Indebtedness, Bank is
relying upon Borrower's representations, warranties, and agreements, as set
forth in the Existing Loan Documents. Except as expressly modified pursuant to
this Loan Modification Agreement, the terms of the Existing Loan Documents
remain unchanged and in full force and effect. Bank's agreement to modifications
to the existing Obligations pursuant to this Loan Modification Agreement in no
way shall obligate Bank to make any future modifications to the Obligations.
Nothing in this Loan Modification Agreement shall constitute a satisfaction of
the Obligations. It is the intention of Bank and Borrower to retain as liable
parties all makers and endorsers of Existing Loan Documents, unless the party is
expressly released by Bank in writing. Unless expressly released herein, no
maker, endorser, or guarantor will be released by virtue of this Loan
Modification Agreement. The terms of this paragraph apply not only to this Loan
Modification Agreement, but also to all subsequent loan modification agreements.

8. CONDITIONS. The effectiveness of this Loan Modification Agreement is
conditioned upon payment of the Loan Fee.

        This Loan Modification Agreement is executed as of the date first
written above.

BORROWER:                                   BANK:

INTRABIOTICS PHARMACEUTICALS, INC.          SILICON VALLEY BANK

By: /s/  Eric Bjerkholt                     By: /s/  Ronald Kundich
   ---------------------------------           ---------------------------------
Name: Eric Bjerkholt                        Name: Ronald Kundich
     -------------------------------             -------------------------------
Title: CFO                                  Title: V.P.
      -------------------------------             ------------------------------

<PAGE>

[SILICON VALLEY BANK LOGO]

                               SILICON VALLEY BANK

                       PRO FORMA INVOICE FOR LOAN CHARGES

BORROWER:                INTRABIOTICS PHARMACEUTICALS, INC.

LOAN OFFICER:            RON  KUNDICH

DATE:                    APRIL 29, 2002

                         LOAN FEE                         $7,500.00
                         DOCUMENTATION FEE                $  250.00

                         TOTAL FEE DUE                    $7,750.00
                                                          =========
PLEASE INDICATE THE METHOD OF PAYMENT:

        { } A CHECK FOR THE TOTAL AMOUNT IS ATTACHED.

        { } DEBIT DDA # __________________ FOR THE TOTAL AMOUNT.

        { } LOAN PROCEEDS

--------------------------------------
BORROWER                     (DATE)

--------------------------------------
SILICON VALLEY BANK          (DATE)
ACCOUNT OFFICER'S SIGNATURE

<PAGE>

                                    EXHIBIT C
                             COMPLIANCE CERTIFICATE

TO:      SILICON VALLEY BANK
         3003 Tasman Drive
         Santa Clara, CA 95054

FROM:    INTRABIOTICS PHARMACEUTICALS, INC.

        The undersigned authorized officer of IntraBiotics Pharmaceuticals, Inc.
("Borrower") certifies that under the terms and conditions of the Amended and
Restated Loan and Security Agreement between Borrower and Bank (the
"Agreement"), (i) Borrower is in complete compliance for the period ending
_______________ with all required covenants except as noted below and (ii) all
representations and warranties in the Agreement are true and correct in all
material respects on this date. Attached are the required documents supporting
the certification. The Officer certifies that these are prepared in accordance
with Generally Accepted Accounting Principles (GAAP) consistently applied from
one period to the next except as explained in an accompanying letter or
footnotes. The Officer acknowledges that no borrowings may be requested at any
time or date of determination that Borrower is not in compliance with any of the
terms of the Agreement, and that compliance is determined not just at the date
this certificate is delivered.

                PLEASE INDICATE COMPLIANCE STATUS BY CIRCLING YES/NO UNDER
"COMPLIES" COLUMN.

<TABLE>
<CAPTION>
  REPORTING COVENANT              REQUIRED                              COMPLIES
  ------------------              --------                              --------
 <S>                              <C>                                   <C>
  Financial statements + CC       *Monthly within 30 days               Yes   No
  Annual (Audited)                FYE within 95 days                    Yes   No
  Annual Projections (approved)   FYE within 30 days                    Yes   No
  10-Q, 10-K and 8-K              Within 5 days after filing with SEC   Yes   No
</TABLE>

*MONTHLY REPORTING applies as of any month-end, Borrower's Liquidity Coverage
falls below 2.50 times the outstanding balances under all Bank term debt or 6
months Remaining Months Liquidity.

<TABLE>
<CAPTION>
 FINANCIAL COVENANT              REQUIRED                   ACTUAL      COMPLIES
 ------------------              --------                   ------      --------
 <S>                             <C>                       <C>          <C>
 Maintain on a Quarterly Basis:
  Minimum Liquidity Coverage     2x balance of all Bank    _____:1.00   Yes   No
                                 term debt and 3 months
                                 Remaining Months
                                 Liquidity

Performance Covenant             **                                     Yes   No

Maximum Loss:                    Quarterly***              $            Yes   No
                                                            --------
</TABLE>

**Borrower will submit its Performance Covenant to Bank on or prior to May 10,
2002

***Borrower shall not report quarterly losses in excess of 20% of its projection
approved by its Board of Directors.

Have there been updates to Borrower's intellectual property?            Yes / No

Borrower only has deposit accounts located at the following
institutions:_______________________________.

<PAGE>

COMMENTS REGARDING EXCEPTIONS:  See Attached.

Sincerely,

IntraBiotics Pharmaceuticals, Inc.

-----------------------------------------
SIGNATURE

-----------------------------------------
TITLE

-----------------------------------------
DATE

                                                         BANK USE ONLY

                                     Received by:
                                                 -------------------------------
                                                        AUTHORIZED SIGNER

                                     Date:
                                          --------------------------------------

                                     Verified:
                                              ----------------------------------
                                                       AUTHORIZED SIGNER

                                     Date:
                                          --------------------------------------

                                     Compliance Status:               Yes     No<PAGE>
                                                                   EXHIBIT 10.32

--------------------------------------------------------------------------------

NOTICE OF GRANT OF STOCK OPTIONS                INTRABIOTICS PHARMACEUTICALS INC
AND OPTION AGREEMENT                            ID: 94-3200380
                                                1245 Terra Bella Avenue
                                                Mountain View, CA  94043
                                                650-526-6800

--------------------------------------------------------------------------------

ERNEST MARIO                                    OPTION NUMBER:  00000619
555 BYRON STREET #401                           PLAN:           2002
PALO ALTO, CA USA 94301                         ID:             ###-##-####

--------------------------------------------------------------------------------

Effective 4/23/2002, you have been granted a(n) Non-Qualified Stock Option to
buy 650,000 shares of IntraBiotics Pharmaceuticals Inc (the Company) stock at
$4.0200 per share.

The total option price of the shares granted is $2,613,000.00.

Shares in each period will become fully vested on the date shown.

<TABLE>
<CAPTION>
         Shares       Vest Type        Full Vest       Expiration
        --------      ---------        ----------      ----------
<S>                  <C>               <C>             <C>
        216,666      On Vest Date      04/24/2003      04/23/2012
        216,667      On Vest Date      04/24/2004      04/23/2012
        216,667      On Vest Date      04/24/2005      04/23/2012
</TABLE>

--------------------------------------------------------------------------------

By your signature and the Company's signature below, you and the Company agree
that these options are granted under and governed by the terms and conditions of
the Company's Stock Option Plan as amended and the Option Agreement, all of
which are attached and made a part of this document.

--------------------------------------------------------------------------------

     /s/ Henry J. Fuchs, M.D.
----------------------------------------        --------------------------------
IntraBiotics Pharmaceuticals Inc                Date

     /s/ Ernest Mario                           6/5/02
----------------------------------------        --------------------------------
Ernest Mario                                    Date

<PAGE>
                       INTRABIOTICS PHARMACEUTICALS, INC.
                             STOCK OPTION AGREEMENT
                           (NONSTATUTORY STOCK OPTION)
                             AMENDED AUGUST 1, 2002

      Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Stock
Option Agreement, IntraBiotics Pharmaceuticals, Inc. (the "Company") has granted
you a nonstatutory stock option to purchase the number of shares of the
Company's Common Stock indicated in your Grant Notice at the exercise price
indicated in your Grant Notice.

      The details of your option are as follows:

      1. DEFINITIONS.

      (a) "AFFILIATE" means any parent corporation or subsidiary corporation of
the Company, whether now or hereafter existing, as those terms are defined in
Sections 424(e) and (f), respectively, of the Code.

      (b) "CAUSE" means that, in the reasonable determination of the Company,
you:

            (i) have been indicted or convicted of any felony or any crime
involving dishonesty that is likely to inflict or has inflicted demonstrable and
material injury on the business of the Company;

            (ii) have participated in any fraud against the Company; or

            (iii) have intentionally damaged any property of the Company thereby
causing demonstrable and material injury to the business of the Company;

provided that Cause shall not exist based on conduct described in clause (ii) or
clause (iii) unless the conduct described in such clause has not been cured
within fifteen (15) days following your receipt of written notice from the
Company specifying the particulars of the conduct constituting Cause.

      (c) "CONTINUOUS SERVICE" means that your service with the Company or an
Affiliate, whether as an employee, director or consultant, is not interrupted or
terminated. Your Continuous Service shall not be deemed to have terminated
merely because of a change in the capacity in which you render service to the
Company or an Affiliate as an employee, consultant or director or a change in
the entity for which you render such service, provided that there is no
interruption or termination of your service. For example, a change in status
without interruption from an employee of the Company to a consultant of an
Affiliate or a director will not constitute an interruption of Continuous
Service. The Board of Directors or the chief executive officer of the Company,
in that party's sole discretion, may determine whether Continuous Service shall
be considered interrupted in the case of any leave of absence approved by that
party, including sick leave, military leave or any other personal leave.

                                       1.
<PAGE>

      (d) "DISABILITY" means the permanent and total disability of a person
within the meaning of Section 22(e)(3) of the Code.

      (e) "FAIR MARKET VALUE" means, as of any date, the value of the Common
Stock determined as follows:

            (i) If the Common Stock is listed on any established stock exchange
or traded on the Nasdaq National Market or the Nasdaq SmallCap Market, the Fair
Market Value of a share of Common Stock shall be the closing sales price for
such stock (or the closing bid, if no sales were reported) as quoted on such
exchange or market (or the exchange or market with the greatest volume of
trading in the Common Stock) on the last market trading day prior to the day of
determination, as reported in The Wall Street Journal or such other source as
the Board deems reliable.

            (ii) In the absence of such markets for the Common Stock, the Fair
Market Value shall be determined in good faith by the Board of Directors.

      (f) "SECURITIES ACT" means the Securities Act of 1933, as amended.

      2. VESTING. Subject to the limitations contained herein, your option will
vest as provided in your Grant Notice, provided that vesting will cease upon the
termination of your Continuous Service.

      3. NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common
Stock subject to your option and your exercise price per share referenced in
your Grant Notice may be adjusted from time to time. If any change is made in
the Common Stock subject to your option, without the receipt of consideration by
the Company (through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, stock
split, liquidating dividend, combination of shares, exchange of shares, change
in corporate structure or other transaction not involving the receipt of
consideration by the Company), your option will be appropriately adjusted in the
class(es) and number of securities and price per share of Common Stock subject
to your option. The Board of Directors shall make such adjustments, and its
determination shall be final, binding and conclusive. (The conversion of any
convertible securities of the Company shall not be treated as a transaction
"without receipt of consideration" by the Company.)

      4. METHOD OF PAYMENT. Payment of the exercise price is due in full upon
exercise of all or any part of your option. You may elect to make payment of the
exercise price in cash or by check or in any other manner PERMITTED BY YOUR
GRANT NOTICE, which may include one or more of the following:

            (a) In the Company's sole discretion at the time your option is
exercised and provided that at the time of exercise the Common Stock is publicly
traded and quoted regularly in The Wall Street Journal, pursuant to a program
developed under Regulation T as promulgated by the Federal Reserve Board that,
prior to the issuance of Common Stock, results in either the

                                       2.
<PAGE>

receipt of cash (or check) by the Company or the receipt of irrevocable
instructions to pay the aggregate exercise price to the Company from the sales
proceeds.

            (b) Provided that at the time of exercise the Common Stock is
publicly traded and quoted regularly in The Wall Street Journal, by delivery of
already-owned shares of Common Stock either that you have held for the period
required to avoid a charge to the Company's reported earnings (generally six
months) or that you did not acquire, directly or indirectly from the Company,
that are owned free and clear of any liens, claims, encumbrances or security
interests, and that are valued at Fair Market Value on the date of exercise.
"Delivery" for these purposes, in the sole discretion of the Company at the time
you exercise your option, shall include delivery to the Company of your
attestation of ownership of such shares of Common Stock in a form approved by
the Company. Notwithstanding the foregoing, you may not exercise your option by
tender to the Company of Common Stock to the extent such tender would violate
the provisions of any law, regulation or agreement restricting the redemption of
the Company's stock.

      5. WHOLE SHARES. You may exercise your option only for whole shares of
Common Stock.

      6. SECURITIES LAW COMPLIANCE. Notwithstanding anything to the contrary
contained herein, you may not exercise your option unless the shares of Common
Stock issuable upon such exercise are then registered under the Securities Act
or, if such shares of Common Stock are not then so registered, the Company has
determined that such exercise and issuance would be exempt from the registration
requirements of the Securities Act. The exercise of your option must also comply
with other applicable laws and regulations governing your option, and you may
not exercise your option if the Company determines that such exercise would not
be in material compliance with such laws and regulations.

      7. TERM. You may not exercise your option before the commencement of its
term or after its term expires. The term of your option commences on the Date of
Grant and expires upon the EARLIEST of the following:

            (a) One (1) week immediately following termination of your
Continuous Service for Cause;

            (b) three (3) months after the termination of your Continuous
Service for any reason other than Cause, Disability or death, provided that if
during any part of such three- (3-) month period you may not exercise your
option solely because of the condition set forth in the preceding paragraph
relating to "Securities Law Compliance," your option shall not expire until the
earlier of the Expiration Date or until it shall have been exercisable for an
aggregate period of three (3) months after the termination of your Continuous
Service;

            (c) twelve (12) months after the termination of your Continuous
Service due to your Disability;

                                       3.
<PAGE>

            (d) eighteen (18) months after your death if you die either during
your Continuous Service or within three (3) months after your Continuous Service
terminates for any reason other than Cause;

            (e) the Expiration Date indicated in your Grant Notice; or

            (f) the day before the tenth (10th) anniversary of the Date of
Grant.

      8. EXERCISE.

            (a) You may exercise the vested portion of your option (and the
unvested portion of your option if your Grant Notice so permits) during its term
by delivering a Notice of Exercise (in a form designated by the Company)
together with the exercise price to the Secretary of the Company, or to such
other person as the Company may designate, during regular business hours,
together with such additional documents as the Company may then require.

            (b) By exercising your option you agree that, as a condition to any
exercise of your option, the Company may require you to enter into an
arrangement providing for the payment by you to the Company of any tax
withholding obligation of the Company arising by reason of (1) the exercise of
your option, (2) the lapse of any substantial risk of forfeiture to which the
shares of Common Stock are subject at the time of exercise, or (3) the
disposition of shares of Common Stock acquired upon such exercise.

      9. TRANSFERABILITY. Your option is not transferable, except by will or by
the laws of descent and distribution, and is exercisable during your life only
by you. Notwithstanding the foregoing, by delivering written notice to the
Company, in a form satisfactory to the Company, you may designate a third party
who, in the event of your death, shall thereafter be entitled to exercise your
option.

      10. STOCKHOLDER RIGHTS. You shall not be deemed to be the holder of, or to
have any of the rights of a holder with respect to, any shares of Common Stock
subject to your option unless and until you have satisfied all requirements for
exercise of your option pursuant to its terms.

      11. OPTION NOT A SERVICE CONTRACT. Your option is not an employment or
service contract, and nothing in your option shall be deemed to create in any
way whatsoever any obligation on your part to continue in the employ of the
Company or an Affiliate, or of the Company or an Affiliate to continue your
employment. In addition, nothing in your option shall obligate the Company or an
Affiliate, their respective shareholders, Boards of Directors, Officers or
Employees to continue any relationship that you might have as a Director or
Consultant for the Company or an Affiliate.

      12. WITHHOLDING OBLIGATIONS.

            (a) At the time you exercise your option, in whole or in part, or at
any time thereafter as requested by the Company, you hereby authorize
withholding from payroll and any

                                       4.
<PAGE>

other amounts payable to you, and otherwise agree to make adequate provision for
(including by means of a "cashless exercise" pursuant to a program developed
under Regulation T as promulgated by the Federal Reserve Board to the extent
permitted by the Company), any sums required to satisfy the federal, state,
local and foreign tax withholding obligations of the Company or an Affiliate, if
any, which arise in connection with your option.

            (b) Upon your request and subject to approval by the Company, in its
sole discretion, and compliance with any applicable conditions or restrictions
of law, the Company may withhold from fully vested shares of Common Stock
otherwise issuable to you upon the exercise of your option a number of whole
shares of Common Stock having a Fair Market Value, determined by the Company as
of the date of exercise, not in excess of the minimum amount of tax required to
be withheld by law. If the date of determination of any tax withholding
obligation is deferred to a date later than the date of exercise of your option,
share withholding pursuant to the preceding sentence shall not be permitted
unless you make a proper and timely election under Section 83(b) of the Code,
covering the aggregate number of shares of Common Stock acquired upon such
exercise with respect to which such determination is otherwise deferred, to
accelerate the determination of such tax withholding obligation to the date of
exercise of your option. Notwithstanding the filing of such election, shares of
Common Stock shall be withheld solely from fully vested shares of Common Stock
determined as of the date of exercise of your option that are otherwise issuable
to you upon such exercise. Any adverse consequences to you arising in connection
with such share withholding procedure shall be your sole responsibility.

            (c) You may not exercise your option unless the tax withholding
obligations of the Company and/or any Affiliate are satisfied. Accordingly, you
may not be able to exercise your option when desired even though your option is
vested, and the Company shall have no obligation to issue a certificate for such
shares of Common Stock or release such shares of Common Stock from any escrow
provided for herein.

      13. NOTICES. Any notices provided for in your option shall be given in
writing and shall be deemed effectively given upon receipt or, in the case of
notices delivered by mail by the Company to you, five (5) days after deposit in
the United States mail, postage prepaid, addressed to you at the last address
you provided to the Company.

      14. CHANGE IN CONTROL. In the event of (i) a sale, lease or other
disposition of all or substantially all of the assets of the Company, (ii) a
merger, consolidation or similar transaction involving (directly or indirectly)
the Company and, immediately after the consummation of such merger,
consolidation or similar transaction, the stockholders of the Company
immediately prior thereto do not own, directly or indirectly, outstanding voting
securities representing more than fifty percent (50%) of the combined
outstanding voting power of the surviving entity (or the parent of the surviving
entity) in such merger, consolidation or similar transaction or (iii) an
acquisition by any person, entity or group within the meaning of Section 13(d)
or 14(d) of the Exchange Act, or any comparable successor provisions (excluding
any employee benefit plan, or related trust, sponsored or maintained by the
Company or an Affiliate) of the beneficial ownership (within the meaning of Rule
13d-3 promulgated under the

                                       5.
<PAGE>

Exchange Act, or comparable successor rule) of securities of the Company
representing at least fifty percent (50%) of the combined voting power of the
Company's then outstanding securities other than by virtue of a merger,
consolidation or similar transaction, then your option shall become fully vested
and immediately exercisable as of the effective date of such transaction.

      15. AMENDMENT OF STOCK OPTION. The Board at any time, and from time to
time, may amend the terms of your option; provided, however, that the rights
under your option shall not be impaired by any such amendment unless (i) the
Company requests your consent and (ii) you consent in writing.

      16. CHOICE OF LAW. The law of the State of Delaware shall govern all
questions concerning the construction, validity and interpretations of your
option, without regard to such state's conflict of laws rules.

                                       6.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]